Skip to main content

Announced · Sweden · Pharma and biotech

ANI Pharmaceuticals to acquire Egetis Therapeutics.

ANI Pharmaceuticals, a Nasdaq-listed pharmaceutical company based in Princeton, New Jersey, announced on 5 November 2026 a recommended public cash offer of SEK 11.25 per share for Egetis Therapeutics, a Nasdaq Stockholm-listed rare disease company headquartered in Stockholm. Shareholders holding about 42.2 percent of the shares have undertaken to accept; the acceptance period is expected to run from about 20 November to 18 December 2026. It was announced on 5 November 2026 and had not been signed by 5 November 2026.

SigningDay 100

Announced 5 November 2026

Buyer
ANI Pharmaceuticals, Inc. ·Princeton, United States
Target
Egetis Therapeutics AB (publ) ·Stockholm, Sweden
Type
Acquisition
Announced
5 November 2026
Value
about SEK 5,304 million (SEK 11.25 per share)
People
Not stated in the release
Last checked
5 November 2026

The people side in Sweden

Related deals

Get the briefing

Deals into Europe lists public facts with their sources, checked every working day by Octagon Professionals International. Corrections go to info@octagon.nl and are made within one working day. How we track deals.

Enabling organisations to operate across borders with clarity, compliance, and trust.

All deals into Europe